Dynavax Technologies | DVAX - Pre Utilidad Fiscal



Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 4.38B 1.92B 2025-09
Adma Biologics USD 61.59M 14.07M 2025-12
Agenus USD -10.61M 263.52M 2025-12
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 3.24B 117M 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Gilead Sciences USD 3.64B 1.21B 2025-09
Glaxosmithkline GBP 2.46B 569M 2025-09
Merck USD 6.74B 22M 2025-09
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
TG Therapeutics USD 45.09M 19.18M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09